DURHAM, N.C., June 11, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announces the expansion of the strategic collaboration between Fresenius Medical Care, the world’s largest provider of dialysis products and services. Under the expanded collaboration, Fresenius Medical Care will have the exclusive rights to commercialize Humacyte’s 6 millimeter x 42 centimeter human acellular vessel and all improvements thereto, and modifications and derivatives thereof (HAVs) in vascular trauma outside of the United States.

By A Silva